Diabeloop's DBLG2 Gets CE Mark, Adds Dexcom G7

Diabeloop said it has won CE clearance for its DBLG2 automated insulin delivery system and will roll the product out across Europe in stages, paired with a continuous glucose monitor and a patch-style insulin delivery device.

The DBLG2 system runs as a smartphone application that hosts Diabeloop’s next‑generation closed‑loop algorithm. The software reads CGM data, predicts glucose trends and sends insulin commands to a compatible pump.

Diabeloop’s public materials trace the regulatory timeline: the company reported CE MDR certification in August 2025 and in May 2026 announced the technical readiness and phased European launch of DBLG2 integrated with a modern CGM and ViCentra’s Kaleido patch pump.

The announcement specifically highlights integration with a newer generation CGM and the Kaleido patch pump, with initial commercial deliveries scheduled first in Germany and the Netherlands and further country rollouts to follow. ViCentra said first deliveries are planned for later this summer.

Diabeloop framed DBLG2 as an evolution of its earlier DBLG1 algorithm and a move toward a software‑centric model that runs on patients’ own phones rather than on dedicated hardware. The company points to real‑world data from its previous system to justify confidence in its therapy model.

The product has also moved through U.S. regulatory review. The FDA’s 510(k) decision documents and Diabeloop press materials indicate DBLG2 obtained U.S. clearance in late 2025, positioning the algorithm as interoperable with cleared pumps and iCGMs.

For clinicians and patients the practical change is modularity: an interoperable algorithm on a smartphone can be paired with certified CGMs and alternate‑controller‑enabled pumps, creating multiple device configurations for the same core software. Diabeloop and partners say this increases choice and speeds market access.

ViCentra’s commercial statement described Kaleido combined with DBLG2 and a modern CGM as a “smartphone‑controlled” hybrid closed‑loop experience, and said the company will transition existing users from DBLG1 to DBLG2 as the new configuration becomes available. Availability will vary by country and by reimbursement pathway.

Regulators and product documents make safety limits explicit. The FDA summary spells out intended uses, age ranges, contraindications and modes of operation for DBLG2, including conditions that return control to a physician‑prescribed basal plan when communications fail. These details determine which patients are appropriate candidates.

The rollout highlights how regulated medical AI systems reach European patients: manufacturers must clear the MDR gate, demonstrate clinical and technical performance, and then navigate country‑level reimbursement and distribution. Diabeloop’s phased approach reflects those parallel steps.

Industry observers say the combination of CE marking under MDR and U.S. 510(k) clearance underscores a broader trend — AI‑driven therapy engines are increasingly modular, interoperable and being commercialized through partnerships between algorithm developers, pump makers and CGM companies. Diabeloop’s recent partner announcements fit that pattern.

For patients the immediate impact will be incremental: new device pairings that promise less hardware, a phone‑based interface and automated insulin adjustments. For regulators and health systems it’s a test of how well oversight, device interoperability and reimbursement rules align with rapidly evolving medical AI products.